Certara, Inc. (CERT)

Market Cap	2.55B
Revenue (ttm)	354.34M
Net Income (ttm)	-55.36M
Shares Out	159.86M
EPS (ttm)	-0.35
PE Ratio	n/a
Forward PE	36.01
Dividend	n/a
Ex-Dividend Date	n/a

Volume	578,031
Open	16.24
Previous Close	16.21
Day's Range	15.83 - 16.35
52-Week Range	11.81 - 24.96
Beta	1.63
Analysts	Hold
Price Target	46.81 (+193.85%)
Earnings Date	May 7, 2024

About CERT

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new dr...

• Industry: Health Information Services
• Sector: Healthcare
• IPO Date: Dec 11, 2020
• Employees: 1,391
• Stock Exchange: NASDAQ
• Ticker Symbol: CERT

Analyst Forecast

According to 10 analysts, the average rating for CERT stock is "Hold." The 12-month stock price forecast is $46.81, which is an increase of 193.85% from the latest price.

Price Target

$46.81

(193.85% upside)

Analyst Consensus: Hold